pumitamig

Pumitamig (BNT327, BMS-986545) is an investigational bispecific antibody developed through a collaboration between BioNTech and Bristol Myers Squibb. It is designed to simultaneously target programmed cell death 1 ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A). By binding to PD-L1, pumitamig aims to restore the activity of effector T cells within the tumor microenvironment by blocking the PD-1/PD-L1 inhibitory checkpoint. Concurrently, its neutralization of VEGF-A is intended to inhibit tumor-induced angiogenesis and alleviate the immunosuppressive effects associated with high VEGF levels. This dual mechanism is being explored to improve clinical outcomes in various solid tumors, including recurrent glioblastoma, non-small cell lung cancer, and triple-negative breast cancer.

Other names

anti-PD-L1/anti-VEGF-A bispecific antibody